A nemia is a common complication seen in intensive care unit (ICU) patients (1) (2) (3) (4) (5) (6) . Its diagnosis cannot be validated clinically, and historically has required confirmation through laboratory analysis of a patient blood sample. In the United States, invasive hemoglobin measurement is performed over 400 million times per year (4) . Blood loss from phlebotomy causes iatrogenic anemia, with over 90% of ICU patients becoming anemic by the third day of ICU admission (6) .
The method of reference for hemoglobin determination is the cyanomethemoglobin method (7) , but this method is costly and time consuming and therefore not practical for clinical use. Laboratory hematology analyzers that utilize the cyanomethemoglobin reaction for hemoglobin estimation are being replaced with cyanide-free technologies that utilize sodium lauryl sulfate to determine hemoglobin concentration. These cyanide-free hematology analyzers show excellent agreement with those utilizing the cyanomethemoglobin method (7, 8) and have become the de facto clinical standard for measuring hemoglobin. Other methods of estimating hemoglobin concentration, such as CO oximeters and point-of-care devices, are commonly used in the hospital environment but are not as accurate as hematology analyzers and still require an invasive sample.
In contrast, the noninvasive Pulse COOximeter provides an immediate and continuous estimation of hemoglobin concentration noninvasively, and so has the potential to improve ICU patient care. The primary objective of this study was to determine whether noninvasive hemoglobin measurement by Pulse CO-Oximetry could provide clinically acceptable accuracy in an ICU setting, defined as absolute and trend accuracy comparable to common invasive methods of a COOximeter and a point-of-care device, when all are compared to the clinical gold standard, the hematology analyzer.
MATERIALS AND METHODS
This prospective, observational study was conducted in a 15-bed surgical ICU at the University Hospital in Poitiers, France. After obtaining ethics committee approval and informed consent, adult patients admitted to the ICU and in need of arterial blood draws for standard care were enrolled in the study. Patients wore Rainbow adult resposable sensors (R2-25, Revision E) connected to a Radical-7 Pulse CO-Oximeter, software version 7.6.0.1 (Masimo, Irvine, CA), for continuous and noninvasive measurement of total hemoglobin (SpHb), SpO 2 , pulse rate, and perfusion index, an indicator of localized perfusion. Sensors were applied to the patient following the di-rections for use provided by the manufacturer. This included the application of the adhesive portion of the sensor so that the emitter and detector were precisely aligned on the finger. Sensors were covered with opaque shields to prevent optical interference. The sensor position was checked before every reading and readjusted if the adhesive portion became misaligned. For invasive measures of hemoglobin, arterial blood was drawn into standard blood collection tubes appropriate for the method of analysis. Reference hemoglobin values were obtained by analyzing arterial blood samples at the laboratory using a Sysmex XT-2000i automated hematology analyzer (Roche Diagnostics, Paris, France). The Sysmex analyzer was calibrated daily according to manufacturer's instructions and good laboratory practice. The Sysmex XT series hematology analyzers measure hemoglobin by colorimetry using the cyanide-free, sodium lauryl sulfate method, and its confidence limits provided by the manufacturer are Ϯ0.2 g/dL. The same samples were also analyzed with a satellite lab COOximeter (Siemens RapidPoint 405 COOximeter, Siemens, Munich, Germany) and a point-of-care hemoglobinometer (HemoCue, Hb201ϩ, Ångelholm, Sweden). The Siemens RapidPoint CO-Oximeter was calibrated daily under the control of the central laboratory. The HemoCue point-of-care device is factory calibrated against the cyanomethemoglobin method and does not require recalibration. The Pulse CO-Oximeter is self-calibrating. Precision of the test devices was assessed by using patients' blood samples (n ϭ 28 to 50 per each clinically meaningful level) measured two times and expressed as coefficient of variation (CV, %). Within-day and between-day imprecision for the satellite lab CO-Oximeter, the HemoCue device, and the Pulse COOximeter were 1.70% and 1.83%, 2.81% and 3.11%, and 1.83% and 2.07% at low hemoglobin levels (7-10 g/dL); 2.40% and 2.21%, 2.70% and 2.92%, and 1.90% and 2.21% at intermediate hemoglobin levels (10 -12 g/dL); and 1.67% and 1.77%, 1.90% and 2.10%, and 1.70% and 1.99% at high hemoglobin levels (12-15 g/dL), respectively. The corresponding quality control specifications of the laboratory reference method were 0.90% and 1.40% at low hemoglobin levels, 0.94% and 1.50% at intermediate levels, and 1.10 and 1.98% at high hemoglobin levels. Invasive hemoglobin values were compared to the noninvasive hemoglobin values obtained at the time of the blood draw. Patients' characteristics, indication for ICU admission (medical or surgical), Simplified Acute Physiology Score II (9) and Sequential Organ Failure Assessment scores (10) at admission, and norepinephrine use were prospectively recorded.
Statistical Analysis
Data are reported as mean values and sd if normally distributed and as median values and minimum-maximum range if the distribution is non-normal. A regression was calculated using the Passing and Bablok procedure (11) . Laboratory assessment of hemoglobin was regarded as the gold standard, and the satellite lab CO-Oximeter, HemoCue point-of-care device, and pulse CO-Oximeter as methods of comparison. The concordance correlation coefficient was calculated. Agreement between laboratory and test devices was performed as described by Bland and Altman (12) . In this study, multiple hemoglobin measurements per patient provided unequal numbers of replicated data in pairs. With clustered observations, adjustment is necessary, so mean bias and limits of agreement were estimated by a component of variance technique (13) . Accuracy of each method compared to the reference method was calculated using accuracy root mean square (A RMS ) with the formula
2 ). The ability of the test devices to follow the trend of the changes in hemoglobin values reported by the reference device was assessed by plotting the difference between subsequent measurements reported by each device to the difference in subsequent measurements reported by the reference device. Coefficient of determination (R 2 ) was calculated for each trend plot as a measure of the goodness of fit of the change in values of the test device compared to the expected change represented by the change in values of the reference device. For two-tailed tests, a p value lower than .05 was considered statistically significant. Ninety-five percent confidence intervals (95% CI) were calculated when required. All data management and statistical analysis was made with R software version 2.11.0 (R Development Core Team, Vienna, Austria).
RESULTS
Of the 65 patients enrolled in the study, three were excluded due to inability to obtain a noninvasive hemoglobin reading with the Pulse CO-Oximeter. The characteristics of the remaining 62 subjects are shown in Table 1 . Subjects were monitored with the device from 1 to 15 days, with a median monitoring time of 6 days.
A total of 471 samples were drawn with an average of 8 Ϯ 4 samples taken per patient. Half of the measurements were performed in sedated subjects and 160 of them (34%) in patients receiving continuous norepinephrine at a dosage between 0.02 and 3.00 g/kg/min (median 0.30 g/kg/min). At each time point, a hemoglobin value was obtained for each of the four methods. Hemoglobin ranged from 6.6 g/dL to 14.9 g/dL (mean 10.0 Ϯ 1.1 g/dL) on the laboratory hematology analyzer, 6.3 g/dL to 14.9 g/dL (mean 10.0 Ϯ 1.0 g/dL) on the Pulse COOximeter, 7.1 g/dL to 17.0 g/dL (mean 10.9 Ϯ 1.2 g/dL) on the satellite lab COOximeter, and 6.5 g/dL to 17. (Fig. 1) , compared to the reference device. The corresponding concordance correlation coefficient was equal to 0.79 (95% CI 0.76; 0.82), 0.74 (95% CI 0.72; 0.77), and 0.76 (95% CI 0.73; 0.80) for Pulse CO-Oximeter, satellite lab COOximeter, and HemoCue point-of-care device, respectively. Bland Altman plots for each test analyzer compared to the reference analyzer are depicted in Figure  2 ; each point represents a patient. Compared to the reference device, the bias and limits of agreement were 0.0 Ϯ 1.0 g/dL for the Pulse CO-Oximeter, 0.9 Ϯ 0.6 g/dL for the satellite lab CO-Oximeter, and 0.3 Ϯ 1.3 g/dL for the HemoCue point-of-care device. All three device measurements appeared to have approximately equal bias throughout the hemoglobin range. Table 2 shows differences between SpHb and laboratory hemoglobin according to laboratory hemoglobin ranges. The highest accuracy (lowest 
DISCUSSION
To the best of our knowledge, we report the first study comparing the performance of Pulse CO-Oximetry and two techniques commonly used in the ICU, a satellite lab CO-Oximeter and the HemoCue point-of-care device, to a central laboratory device to estimate true and dynamic changes of hemoglobin levels in ICU patients. The noninvasive Pulse CO-Oximetry had the best accuracy as evidenced by the highest concordance coefficient correlation and the lowest A RMS . Neither the administration of norepinephrine nor low perfusion state influenced the accuracy of the device. Only three patients (5%) with very poor peripheral perfusion had to be excluded because of the inability to obtain any SpHb reading, despite careful sensor repositioning. The satellite lab CO-Oximeter displayed the most pronounced bias (0.9 g/dL), leading to a constant overestimation of hemoglobin concentration. However, the precision of this device was better than both the Pulse CO-Oximeter and the point-of-care device, as assessed by the lowest agreement limits from Bland Altman plots. The point-of-care device displayed the most pronounced scattering of the three test devices compared to the results of the reference method, as demonstrated by the lowest concordance coefficient correlation and the widest limits of agreement from Bland Altman plot.
The Pulse CO-Oximetry has been previously evaluated, mainly in surgical patients or healthy volunteers exposed to hemodilution (4) . Most of the studies are not yet published and results are only available through abstracts. Software and sensor versions used in these studies are not always specified. When this information is available, the software version was older than the one we used in the present study. SpHb readings were compared with corresponding, laboratory-measured hemoglobin levels. Bias and limits of agreement according to Bland Altman procedure were not always determined. When available, bias was usually lower than Ϯ 0.5 g/dL, precision comprised between 0.3 and 2.4 g/dL, and accuracy, expressed as A RMS value, comprised between 0.5 to 1.4 g/dL (4, 14 -16, and unpublished data). These inconsistent results may be explained, at least in part, by different versions of both the Masimo SpHb sensor and the software used in these studies. Indeed, in prior tests (unpublished data), when we compared the bias and precision of 305 SpHb readings in 50 ICU patients using older versions of the Masimo SpHb sensor (R2-25, Revision C) and software (7.0.4.9) to the current study results, the bias (Ϫ0.31 vs. 0.0 g/dL), precision (1.1 vs. 0.5 g/dL). and accuracy (2.1 vs. 0.8 g/dL) were improved. Similar findings were reported in another study (17) where a total of 228 data pairs were collected from 55 cardiac surgery patients over three device revisions (Versions A, C, and E). The bias (0.4, 0.7, and 0.0 g/dL, respectively) and SD (1.6, 2.4, and 1.1 g/dL) were substantially improved with the use of the most recent iteration of the device.
The HemoCue device has been extensively evaluated, but most of the studies have been conducted outside the ICU. Compared to the reference method, bias and limit of agreement of this point-ofcare device using capillary blood were equal to Ϫ0.3 Ϯ 1.7 g/dL in 204 samples from blood donor patients (18), 0.6 Ϯ 1.2 g/dL in 140 samples from surgical patients (19) , Ϫ0.1 Ϯ 1.7 g/dL in 94 specimens taken from patients with gastrointestinal bleeding (20) , and 0.6 Ϯ 2.4 g/dL in 43 specimens taken from critically ill patients (21) . Our results (Ϫ0.3 Ϯ 1.3 g/dL) are slightly better than these studies, and similar (0.2 Ϯ 1.5 g/dL) to those we observed in a previous study performed during 1,166 hemoglobin determinations in 198 ICU patients (22) . CO-Oximeters are considered accurate in assessing hemoglobin level and have the highest degree of interdevice reliability. In an intradevice comparison of five different CO-Oximeters, there was a range of 0.1 to 1.3 g/dL difference and an average SD of 0.5 g/dL when measuring the same blood sample on two separate devices of the same model type (23) . In an interdevice comparison of 31 different CO-Oximeters, there was a 0.4 to 0.9 g/dL range of difference, depending on what range of hemoglobin was being analyzed.
The ability to measure hemoglobin noninvasively and continuously has significant potential to facilitate hemoglobin monitoring, hasten the detection of acute anemia, and avoid the complications, expense, and discomfort associated with invasive blood draws. The Pulse COOximeter is the first device able to continuously and noninvasively estimate hemoglobin concentration, in addition to other common parameters usually monitored in ICU patients, and therefore provides a significant expansion of existing monitoring technology. Even if our results are encouraging, being slightly better than those previously reported, therapeutic decisions such as blood transfusion should not be based on hemoglobin estimation with the Pulse CO-Oximeter device alone. However, since the noninvasive method showed similar trend accuracy to the invasive method, then the laboratory hemoglobin determination could be limited to situations where a blood transfusion is considered.
Some limitations should be acknowledged. Firstly, Ͻ10% of measures were performed in patients with a hemoglobin concentration below 8 g/dL, so SpHb accuracy at lower hemoglobin concentrations may be different. However, as shown in the Bland Altman plot, the difference between hemoglobin levels given by the laboratory and Pulse CO-Oximeter was not influenced by hemoglobin concentration, making it unlikely that Pulse CO-Oximeter performance would be different with severe anemia. Furthermore, at very low hemoglobin levels, the diagnosis and blood transfusion decisions are based more on the clinical context, clinical signs, and severity of shock rather than hemoglobin assessment. Secondly, none of the included patients had active major bleeding. Having an accurate, continuous, and noninvasive monitor of hemoglobin might be useful in patients with ongoing bleeding, so the accuracy and clinical utility of the Pulse COOximeter in this setting should be evaluated. Finally, the study did not assess the potential advantages of continuous monitoring on blood management and earlier detection of bleeding.
CONCLUSIONS
When compared to laboratory reference values, noninvasive hemoglobin measurement with Pulse CO-Oximetry has absolute and trending accuracy similar to widely used invasive methods of hemoglobin measurement. Noninvasive hemoglobin measurement with Pulse CO-Oximetry has the additional advantage of providing continuous measurements and may be a feasible alternative to invasive hemoglobin monitoring. A laboratory hemoglobin determination could be limited to situations where a blood transfusion is considered.
